Elbehiry A, Marzouk E, Abalkhail A, Abdelsalam M, Mostafa M, Alasiri M
Front Microbiol. 2025; 16:1549044.
PMID: 40071214
PMC: 11893576.
DOI: 10.3389/fmicb.2025.1549044.
Azeez S, Adeboye S
Virusdisease. 2024; 35(3):537-552.
PMID: 39464738
PMC: 11502661.
DOI: 10.1007/s13337-024-00889-4.
Tarafder E, Nizamani M, Karunarathna S, Das D, Zeng X, Rind R
World J Microbiol Biotechnol. 2024; 40(9):275.
PMID: 39034336
DOI: 10.1007/s11274-024-04079-8.
Pratt B
Sci Eng Ethics. 2024; 30(3):25.
PMID: 38842627
PMC: 11156718.
DOI: 10.1007/s11948-024-00487-z.
Ramos P, Almeida M, Olsson I
Front Genome Ed. 2024; 5:1284547.
PMID: 38192431
PMC: 10773783.
DOI: 10.3389/fgeed.2023.1284547.
CRISPR-Cas9 gene editing and human diseases.
Jinka C, Sainath C, Babu S, Chennupati A, Muppidi L, Krishnan M
Bioinformation. 2023; 18(11):1081-1086.
PMID: 37693076
PMC: 10484690.
DOI: 10.6026/973206300181081.
LbCas12a mediated suppression of .
Ashraf S, Ahmad A, Khan S, Jamil A, Sadia B, Brown J
Front Plant Sci. 2023; 14:1233295.
PMID: 37636103
PMC: 10456881.
DOI: 10.3389/fpls.2023.1233295.
Methods of crop improvement and applications towards fortifying food security.
Patel A, Miles A, Strackhouse T, Cook L, Leng S, Patel S
Front Genome Ed. 2023; 5:1171969.
PMID: 37484652
PMC: 10361821.
DOI: 10.3389/fgeed.2023.1171969.
CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance.
Mayorga-Ramos A, Zuniga-Miranda J, Carrera-Pacheco S, Barba-Ostria C, Guaman L
ACS Infect Dis. 2023; 9(7):1283-1302.
PMID: 37347230
PMC: 10353011.
DOI: 10.1021/acsinfecdis.2c00649.
Genome Editing in Human Gametes and Embryos: The Legal Dimension in Europe.
Vidalis T
BioTech (Basel). 2023; 12(1).
PMID: 36648827
PMC: 9844473.
DOI: 10.3390/biotech12010001.
Tailoring Cardiac Synthetic Transcriptional Modulation Towards Precision Medicine.
Schoger E, Lelek S, Panakova D, Zelarayan L
Front Cardiovasc Med. 2022; 8:783072.
PMID: 35097003
PMC: 8795974.
DOI: 10.3389/fcvm.2021.783072.
From Descriptive to Functional Genomics of Leukemias Focusing on Genome Engineering Techniques.
Balla B, Tripon F, Banescu C
Int J Mol Sci. 2021; 22(18).
PMID: 34576226
PMC: 8470190.
DOI: 10.3390/ijms221810065.
delivery of CRISPR-Cas9 therapeutics: Progress and challenges.
Behr M, Zhou J, Xu B, Zhang H
Acta Pharm Sin B. 2021; 11(8):2150-2171.
PMID: 34522582
PMC: 8424283.
DOI: 10.1016/j.apsb.2021.05.020.
CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases.
Rasoulinejad S, Maroufi F
Mol Biotechnol. 2021; 63(9):768-779.
PMID: 34057656
DOI: 10.1007/s12033-021-00345-4.
Unresolved Issues in RNA Therapeutics in Vascular Diseases With a Focus on Aneurysm Disease.
Schellinger I, Dannert A, Mattern K, Raaz U, Tsao P
Front Cardiovasc Med. 2021; 8:571076.
PMID: 33937351
PMC: 8081859.
DOI: 10.3389/fcvm.2021.571076.
CRISPR-Cas and Its Wide-Ranging Applications: From Human Genome Editing to Environmental Implications, Technical Limitations, Hazards and Bioethical Issues.
Piergentili R, Del Rio A, Signore F, Umani Ronchi F, Marinelli E, Zaami S
Cells. 2021; 10(5).
PMID: 33919194
PMC: 8143109.
DOI: 10.3390/cells10050969.
Meaning of Ambiguity: A Japanese Survey on Synthetic Biology and Genome Editing.
Hibino A, Yoshizawa G, Minari J
Front Sociol. 2021; 4:81.
PMID: 33869403
PMC: 8022501.
DOI: 10.3389/fsoc.2019.00081.
Novel CRISPR-Cas Systems: An Updated Review of the Current Achievements, Applications, and Future Research Perspectives.
Nidhi S, Anand U, Oleksak P, Tripathi P, Lal J, Thomas G
Int J Mol Sci. 2021; 22(7).
PMID: 33805113
PMC: 8036902.
DOI: 10.3390/ijms22073327.
Block-And-Lock: New Horizons for a Cure for HIV-1.
Moranguinho I, Valente S
Viruses. 2020; 12(12).
PMID: 33334019
PMC: 7765451.
DOI: 10.3390/v12121443.
Adequacy and sufficiency evaluation of existing EFSA guidelines for the molecular characterisation, environmental risk assessment and post-market environmental monitoring of genetically modified insects containing engineered gene drives.
Naegeli H, Bresson J, Dalmay T, Dewhurst I, Epstein M, Guerche P
EFSA J. 2020; 18(11):e06297.
PMID: 33209154
PMC: 7658669.
DOI: 10.2903/j.efsa.2020.6297.
